Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

被引：0

作者：

Sebastiano Mercadante

Paolo Marchetti

Arturo Cuomo

Massimo Mammucari

Augusto Caraceni

机构：

[1] Anesthesia and Intensive Care & Pain Relief and Supportive Care,Molecular and Clinical Medicine Medical Oncology

[2] La sapienza University of Rome,Abdominal Medical Oncology

[3] National Cancer Institute Pascale,Palliative Care, Pain Therapy and Rehabilitation

[4] Primary Care Unit,Pain Relief and Palliative Care Unit

[5] ASL RME,undefined

[6] National Cancer Institute,undefined

[7] La Maddalena Cancer Center,undefined

来源：

Supportive Care in Cancer | 2016年 / 24卷

关键词：

Breakthrough pain; Opioids; Fentanyl; Morphine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

引用

页码：961 / 968

页数：7

共 49 条

[21]

Davies A(2010)Assessment and classification of cancer breakthrough pain: a systematic literature review Pain 149 476-482

[22]

Bennett D(2007)A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials J Palliat Med 10 47-55

[23]

Hagen NA(2014)Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients J Pain Symptom Manag 48 619-510

[24]

Davies A(2004)Optimization of opioid therapy for preventing incident pain associated with bone metastases J Pain Symptom Manag 28 505-593

[25]

Mercadante S(2001)Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 587-S43

[26]

Haugen D(2013)Evidence-based treatment of cancer-related breakthrough pain with opioids J Natl Compr Cancer Netw 11 S37-190

[27]

Hagen NA(2012)Pharmacotherapy for breakthrough cancer pain Drugs 72 181-580

[28]

Webber K(2013)Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials J Pain Symptom Manag 46 573-2563

[29]

Mercadante S(2013)Opioids for the management of breakthrough pain in cancer patients Cochrane Database Syst Rev 10 CD004311-338

[30]

Hanks GW(2013)A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain Support Care Cancer 21 2557-430

← 1 2 3 4 5 →